Sanofi’s cancer research has delivered valuable scientific insights to the community, leading to new therapies for people battling some of the most difficult-to-treat cancers. But our work to improve the lives of people living with cancer is far from over. Our researchers continue to push the frontiers of science, harnessing new technologies to build a new generation of cancer treatments. These range from innovative molecules that attack or destroy tumor cells to cell therapies designed to help the body’s immune system fight cancer.

At ASCO 2021, we are excited to share our latest research across multiple myeloma, prostate cancer, skin, lung, and breast cancers.

Our R&D teams combine immuno-oncology and molecular oncology approaches. In molecular oncology, revolutionary chemistry is enabling our scientists to design investigational drugs that target intracellular proteins in cancer cells. In immuno-oncology, Sanofi researchers are using novel cell-therapy approaches to stimulate immune cells to fight cancer while working to limit toxic side effects. They are also designing antibody–drug conjugates (ADCs) that selectively target cytotoxic drugs to tumor cells, potentially sparing healthy ones1. Currently, our lung-cancer researchers are exploring how this approach could be used to target a drug to a tumor, where it could potentially inhibit tumor growth by dismantling the cell-division machinery.

By developing targeted cancer therapies designed to minimize toxic side effects, Sanofi researchers aim to make a positive impact on patient health. Our diverse R&D portfolio reflects our strong belief that achieving a step change in cancer R&D – and potentially defeating cancer – will take several complementary approaches and a sustained commitment to perpetual innovation.

We look forward to sharing our efforts in these areas and more at ASCO 2021. For more information on our presence at ASCO 2021, including specific abstracts that will be presented, read our "curtain raiser" press release.

[1] Dan N, Setua S, Kashyap V, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals. June 2018; 11(2):32.

Last Updated: May 2021